Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Jun 14, 2004
HEMISPHERX BIOPHARMA LAUNCHES MULTIPLE SCLEROSIS SALVAGE PROGRAM WITH NATURAL INTERFERONS
Jun 01, 2004
HEMISPHERX BIOPHARMA RECEIVES APPROVAL FOR WEST NILE VIRUS PROTOCOL WITH ALFERON N TREATMENT
May 17, 2004
HEMISPHERX FILES EXPANDED U.S. PATENT APPLICATION FOR TREATING SARS AND EMERGING VIRUSES
May 14, 2004
HEMISPHERX BIOPHARMA FIRST QUARTER 2004 EARNINGS ANNOUNCED
May 10, 2004
HEMISPHERX BIOPHARMA LAUNCHES NEW HIV CLINICAL PROGRAM IN AFRICA WITH COST EFFECTIVE ANTIVIRAL DELIVERY
May 03, 2004
HEMISPHERX BIOPHARMA ANNOUNCES PHASE 3 CHRONIC FATIGUE SYNDROME TRIAL MEETS PRIMARY ENDPOINT
Apr 30, 2004
Hemispherx Biopharma Accelerates Release Date on Phase 3 Data for Ampligen in CFS
Apr 20, 2004
HEMISPHERX BIOPHARMA CEO TO PRESENT AT WHITE MOUNTAIN CAPITAL BIOTECHNOLOGY CONFERENCE
Apr 19, 2004
HEMISPHERX BIOPHARMA REPORTS PUBLICATION SHOWING SUPERIOR ACTIVITY OF ALFERON AGAINST SARS
Apr 13, 2004
Hemispherx Biopharma to Present First Phase 3 Data on Ampligen in Chronic Fatigue Syndrome at the 17th International Conference on Antiviral Research
62
63
64
65
66
67
68
69
70
71
72
<<
<
>
>>
Privacy